ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS
Abstract
The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation.
References
1. Boonen S., Laan R.F., Barton I.P., et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 2005; 16(10): 1291-1298. DOI: 10.1007/s00198-005-1945-x.
2. McCloskey E., Johansson H., Oden A., Kanis J.A. Fracture risk assessment. ClinBiochem. 2012; 45(12): 887-93. doi: 10.1016/j.clinbiochem.2012.05.001. Epub 2012 May 8.
3. Nordin C. et al. US Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011; 154(5): 356-364. doi: 10.7326/0003-4819-155-4-201108160-00021.
4. Клинические рекомендации по остеопорозу Российской ассоциации Эндокринологов (краткое изложение). Остеопороз и остеопатии, 2016 г., № 3.
5. Gourlay M.L., Fine J.P., Preisser J.S., et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012; 366(3): 225-33. doi: 10.1056/NEJMoa1107142.
6. Zhou J., Ma X., Wang T., et al. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016; 27(11): 3289-3300. DOI: 10.1007/s00198-016-3654-z.
7. Crandall C.J., Newberry S.J., Diamant A., et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014; 161(10): 711-723. doi: 10.7326/M14-0317.
8. Serrano A.J., Begona L., Anitua E., et al. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. GynecolEndocrinol.2013 Dec; 29(12): 1005-14. doi: 10.3109/09513590.2013.813468.
9. Davis S., Martyn-St. James M., Sanderson J., et al. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess. 2016; 20(78): 1-406. DOI: 10.3310/hta20780.
10. Zhou J., Ma X., Wang T., et al. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016; 27(11): 3289-3300. DOI: 10.1007/s00198-016-3654-z.
11. McClung M., Miller P., Recknor C., et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol.2009; 114(5): 999-1007. doi: 10.1097/AOG.0b013e3181bdce0a.
12. Watts N.B., Adler R.A., Bilezikian J.P., et al. Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J ClinEndocrinolMetab. 2012; 97(6): 1802-22. doi: 10.1210/jc.2011-3045.
13. Zhou J., Wang T., Zhao X., et al. Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. Rheumatol Ther. 2016; 3(1): 117-128. DOI: 10.1007/s40744-016-0030-6.
14. Reid D.M., Devogelaer J.P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373(9671): 1253-1263. doi: 10.1016/S0140-6736(09)60250-6.
15. Lyles Kw., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18): 1799-1809. DOI: 10.1056/NEJMoa074941.
16. Adler R.A., El-Hajj Fuleihan G., Bauer D.C., et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. Bone Miner Res.2016 Oct; 31(10): 1910. doi: 10.1002/jbmr.2918.
17. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 2004; 843: 1-129.
18. Reid I., Gamble G., Mesenbrink P., et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. J ClinEndocrinolMetab. 2010; 95: 4380-87.doi: 10.1210/jc.2010-0597.
19. Black D., Delmas P., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809-22. DOI: 10.1056/NEJMoa067312.
20. Dicuonzo G., Vincenzi B., Santini D., et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res. 2003; 23: 649-54. DOI: 10.1089/107999003322558782.
21. Perazella M., Markowitz G. Bisphosphonate nephrotoxicity. Kidney Int. 2008; 74: 1385-93. DOI: 10.1038/ki.2008.356.
22. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22: 1479-91. DOI: 10.1359/jbmr.0707onj.
23. Marx R., Sawatari Y., Fortin M., Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63: 1567-75. DOI: 10.1016/j.joms.2005.07.010.
24. John Camm A. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. ClinTher. 2010; 32: 426-36. doi: 10.1016/j.clinthera.2010.03.014.
25. Shane E., Burr D., Ebeling P., et al. Atypical sub trochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25: 2267-94. doi: 10.1002/jbmr.253.
26. Kotian P., Boloor A., Sreenivasan S. Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis.J ClinDiagn Res. 2016 Jan; 10(1): OC04-6. doi: 10.7860/JCDR/2016/17061.7021.
27. Лесняк О.М., Никитинская О.А., Торопцова Н.В., Белая Ж.Е., Белова К.Ю., Бордакова Е.В., Гильманов А.Ж., Гур-кина Е.Ю., Дорофейков В.В., Ершова О.Б., Зазерская И.Е., Зоткин Е.Г., Каронова Т.Л., Марченкова Л.А., Назарова А.В., Пигарова Е.А., Рожинская Л.Я., Сафонова Ю.А., Скрипникова И.А., Ширинян Л.В. и др. Профилактика, диагностика и лечение дефицита витамина D и кальция у взрослого населения России и пациентов с остеопорозом (по материалам подготовленных клинических рекомендаций. Научнопрактическая ревматология. - 2015. - № 4. - С. 403-408. [Lesnyak O.M., Nikitinskaya O.A., Toroptsova N.V., Belaya Z.E., Belova K.Y., Bordakova E.V., Gilmanov A.Z., Gurkina E.Y, Dorofeikov V.V., Ershova O.B., Zazerskaya I.E., Zotkin E.G., Karonova T.L., Marchenkova L.A., Nazarova A.V., Pigarova E.A., Rozhinskaya L.Y, Safonova Y.A., Skripnikova I.A., Shirinyan L.V., Yureneva S.V., Yakushevskaya O.V. The prevention, diagnosis and treatment of vitamin D and calcium deficiencies in the adult population of Russia and in patients with osteoporosis (according to the materials of prepared cliniclrecomendations. Rheumatology Science and Practice.2015; 53(4): 403-408. (InRuss.) DOI: 10.14412/1995-4484-2015-403-408].
28. Пигарова Е.А. Роль кальция в профилактике и лечении остеопороза. Эффективная фармакотерапия. - 2015. - № 46. - С. 34-39. [Pigarova E.A. The pole of calcium in preventing and treatment of osteoporosis. Effective pharmacotherapy. 2015; 46: 34-39].
29. Brown J.J., Zacharin M.R. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab. 2009 Jan; 22(1): 55-63.
30. Vuorimies I., Toiviainen-Salo S., Hero M., et al. Zoledronic acid treatment in children with osteogenesisimperfecta. Horm Res Paediatr.2011; 75(5): 346-53.doi: 10.1159/000323368.
31. Xu X.J., Ma D.D., Lv F., et al. The clinical characteristics and efficacy of bisphosphonates in adult patients with osteogenesisimperfecta. EndocrPract.2016 Aug 2. DOI: 10.4158/EP151184.OR.
32. Sosunova N.V., Belaya Z.E., Dzeranova L.K., et al. The comparative response of biochemical parameters concerning treatment with zoledronic acid 5mg a year in patients with primary hyperparathyroidism and postmenopausal osteoporosis. J. Osteoporosis International. 2010; 21(l): 158-159.
33. Siris E.S., Lyles K.W., Singer F.R., et al. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J Bone Miner Res.2006 Dec; 21Suppl 2: P94-8. DOI: 10.1359/jbmr.06s218.
34. Reid I.R., Miller P., Lyles K., et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. NEnglJ. 2005; Med 353: 898-908. DOI: 10.1056/NEJMoa044241.
35. Lin T.Y., Yang S.C., Tsai T.T., et al. Correlation between zoledronic acid infusion and repeat vertebroplasty surgery in osteoporotic patients. Curr Med Res Opin. 2016 May; 32(5): 921-927. doi: 10.1185/03007995.2016.1151775.
36. Javed F., Vohra F., Zafar S., et al. Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies. Arch Oral Biol. 2014 Sep; 59(9): 912-20.doi: 10.1016/j.archoralbio.2014.05.016.
37. Cardemil C., Omar O.M., Norlindh B., et al. The effects of a systemic single dose of zoledronic acid on post-implantation bone remodelling and inflammation in an ovariectomised rat model. Biomaterials. 2013; 34(5): 1546-61.doi: 10.1016/j.biomaterials.2012.11.003.
38. Viera-Negron Y.E., Ruan W.H., Winger J.N., et al. Effect of ovariectomy and alendronate on implant osseointegration in rat maxillary bone. J Oral Implantol. 2008; 34(2): 76-82. doi: 10.1563/1548-1336(2008)34[76:EOOAAO]2.0.CO;2.
39. Abtahi J., Tengvall P., Aspenberg P. A bisphosphonatecoating improves the fixation of metal implants in human bone. A randomized trial of dental implants.Bone. 2012 May; 50(5): 1148-51.doi: 10.1016/j.bone.2012.02.001.
40. Марченкова Л.А., Древаль А.В., Бахарев И.В. Эффективность и переносимость Резокластина ФС (5 мг) при лечении остеопороза: ретроспективный анализ клинического опыта применения препарата в России. Остеопороз и остеопатии. - 2014. - № 3. - С. 22-26. [Marchenkova L.A., Dreval A.V., Baharev I.V. Efficacy and tolerability of generic zoledronic acid 5 mg (Rezoclastin PS) in the treatment of osteoporosis: a retrospective analysis of clinical experience with the drug in Russia. Osteoporosis and osteopathies. 2014; 3: 22-26].
41. Елисеева Л.Н., Резникова Л.Б., Тихомирова Н.Ю. Опыт применения Резокластина ФС в коррекции нарушений у пациенток с постменопаузальным остеопорозом. Российский вестник акушера-гинеколога. - 2013. - Т. 13. - № 3. - С. 80-82. [Eliseeva L.N., Reznikova L.B., TikhomirovaN.Iu. Experience with Rezoklastin FS in the correction of disorders in patients with postmenopausal osteoporosis. Russianvestnikofobstetricians-gynecologists. 2013; 13(3): 80-82].
42. Куляев Е.А., Графов А.В., Фаламеева О.В., Храпова Ю.В., Садовой М.А. Опыт применения золедроновой кислоты (Резокластин ФС 5 мг/6,25 мл, ЗАО «Ф-Синтез», Россия) у пациентов с низкой минеральной плотностью костной ткани. Эффективная фармакотерапия. - 2013. - № 38. - С. 30-33. [KulyayevY.Yu.,GrafovA.V., Falameyaeva O.V., Khrapova Yu.V., Sadovoy M.A. Study of zoledron i cacidpreparation Rezoklastin FS 5 mg/6.25 ml (F-SintezCJSC) in patients with low bonemi neraldensi ty. Effective pharmacotherapy. 2013; 38: 30-33].
43. Кочиш А.Ю., Иванов С.Н. Сравнительное исследование эффективности отечественного генерика и оригинального препарата золедроновой кислоты у пациенток с малоэнергетическими переломами тел позвонков и постменопаузальным остеопорозом. Фарматека. - 2014. - № 10(2). - С. 24-29. [Sravnitel’noe issledovanie jeffektivnosti otechestvennogo generika i original’nogo preparata zoledronovo jkislotyu pacientoks malojenergeticheskimi perelomami tel pozvonkov i postmenopauzal’nym osteoporozom. Pharmateca. 2014; 10(2): 24-29].
44. Куляев Е.А., Графов А.В., Фаламеева О.В., Холодкин В.С., Садовой М.А. Использование золедроновой кислоты (Резокластина ФС 5 мг/6,25 мл) для профилактики асептической нестабильности металлоконструкций после эндопротезирования тазобедренного или коленного сустава у пациентов с низкой минеральной плотностью ткани. Эффективная фармакотерапия. - 2016. - № 27. - С. 4-8. [Kulyayev Y. Yu., Grafov A.V., Falameyaeva O.V., Kholodkin V.S., Sadovoy M.A. Use of Zoledronic Acid (FS Rezoklastin 5 mg/6.25 ml) in Preventing Aseptic Instability of Metallic Constructs after Hip or Knee Arthroplasty in Patients with Low Mineral Bone Density. Effective pharmacotherapy. 2016; 27: 4-8].
Review
For citations:
Vorotnikova S.Yu., Pigarova E.A. ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS. Osteoporosis and Bone Diseases. 2016;19(3):23-27. (In Russ.)
Views:
123482
Email this article 
